Tracy Riordan, MD
Internal Medicine · Imperial, MONPI 1124094362
Payments from drug & device makers
Across 316 payments — averaging $18.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- AstraZeneca$424
- Pfizer$364
- Novo Nordisk$324
- GSK$291
- Lilly USA, LLC$246
- plus $867 from 20 others
What the payments were for
- Food & beverage$5,710100%
- Education$180%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 166 | $3,213 |
| AstraZeneca | 26 | $424 |
| Pfizer | 21 | $364 |
| Novo Nordisk | 18 | $324 |
| GSK | 21 | $291 |
| Lilly USA, LLC | 15 | $246 |
| Abbott | 6 | $126 |
| Johnson & Johnson | 6 | $93 |
| Amgen | 5 | $80 |
| Exact Sciences | 4 | $79 |
| Novartis | 4 | $61 |
| Astellas Pharma US Inc | 3 | $58 |
| Boehringer Ingelheim | 3 | $50 |
| Endo Pharmaceuticals Inc. | 2 | $40 |
| Corcept Therapeutics | 1 | $36 |
| Merck | 2 | $33 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $32 |
| Supernus Pharmaceuticals, Inc. | 2 | $29 |
| Sunovion Pharmaceuticals Inc. | 2 | $28 |
| Nevro Corp. | 1 | $23 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $20 |
| Tris Pharma Inc | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $17 |
| Shire North American Group Inc | 1 | $16 |
| Circassia Inc. | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $13 |
How this compares
$5,728 in reported general payments places this provider in the 90th percentile of 2,097 internal medicine providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 65 | $59,672 |
| EliquisApixaban | 50 | $58,061 |
| XareltoRivaroxaban | 72 | $52,750 |
| JardianceEmpagliflozin | 33 | $50,216 |
| OzempicSemaglutide | 22 | $43,242 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $24,732 |
| JanuviaSitagliptin Phosphate | 14 | $24,371 |
| JanumetSitagliptin Phos/Metformin Hcl | 16 | $16,468 |
| MounjaroTirzepatide | 13 | $13,780 |
| MyrbetriqMirabegron | 11 | $13,280 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 16 | $10,319 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 14 | $6,443 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 37 | $6,175 |
| Atorvastatin Calcium | 603 | $5,606 |
| SymbicortBudesonide/Formoterol Fumarate | 16 | $5,069 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $424 | $75,06097 claims |
| PfizerEliquis, Abrysvo | $364 | $61,21062 claims |
| Johnson & JohnsonXarelto | $93 | $52,75072 claims |
| Boehringer IngelheimJardiance | $50 | $50,21633 claims |
| Novo NordiskOzempic | $324 | $43,24222 claims |
| MerckJanuvia, Janumet | $33 | $40,83930 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Arexvy | $291 | $34,78350 claims |
| Lilly USA, LLCMounjaro, Humulin 70-30 | $246 | $15,09625 claims |
| Astellas Pharma US IncMyrbetriq | $58 | $13,28011 claims |
| AbbVieSynthroid | $3,213 | $1,44613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,097 internal medicine providers in Missouri.
Other internal medicine in Imperial
- Timothy SmithSaint Peters$21.4M
- Craig DietzKansas City$4M
- Michael ReschakSaint Louis$3.1M
- Dima DandachiColumbia$1.2M
- Santosh SharmaKansas City$782K
- Jianbo WangChesterfield$643K
- David PrelutskySaint Louis$575K
- Danish JabbarSaint Louis$510K
- Dubert GuerreroIndependence$369K
- Hany SalamaSaint Louis$279K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.